Active Ingredient(s): Macimorelin Acetate
FDA Approved: * December 20, 2017
Category: Diagnostic Aid

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Macrilen Overview

Macimorelin (INN) – or Macrilen (trade name) – is a drug that was developed by Æterna Zentaris for use in the diagnosis of adult growth hormone deficiency.[2] Macimorelin acetate, the salt formulation, is a synthetic growth hormone secretagogue receptor agonist.[3] It is s a growth hormone secretagogue receptor (ghrelin receptor) agonist causing release of growth hormone from the pituitary gland.[4][5][6&...

Read more Macrilen Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Macrilen Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Macimorelin Acetate
  • For Solution: 60mg/pouch
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Macrilen: (2 results)

Sorted by National Drug Code
  • 0169-1401 Macrilen 60 mg/mg Oral Granule, for Solution by Novo Nordisk
  • 71090-002 Macrilen 60 mg/mg Oral Granule, for Solution by Strongbridge U.S. Inc

Other drugs which contain Macimorelin Acetate or a similar ingredient: (1 result)